We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biomarker Predicts Mortality Risk for Peripheral Artery Disease Patients

By LabMedica International staff writers
Posted on 04 Nov 2016
Print article
Image: The LCMS‐8050 CL triple quadrupole mass spectrometer (Photo courtesy of Shimadzu).
Image: The LCMS‐8050 CL triple quadrupole mass spectrometer (Photo courtesy of Shimadzu).
Production of the proatherogenic metabolite, trimethylamine N‐oxide (TMAO), from dietary nutrients by intestinal microbiota enhances atherosclerosis and is associated with atherosclerotic coronary artery disease in humans.

Peripheral artery disease (PAD) is a common manifestation of systemic atherosclerosis and is associated with significantly increased cardiovascular death and mortality and it affects over 27 million people across Europe and North America.

Scientists associated with the Cleveland Clinic (Cleveland, OH, USA) carried out a single‐center prospective cohort study and enrolled 821 sequential consenting patients who underwent elective, non-urgent coronary angiographic evaluation at the Cleveland Clinic between 2001 and 2007. A confirmed diagnosis of PAD was based primarily on the type of PAD, based on reporting evidence of stenosis at the corresponding vasculature. Participants were followed for five years between 2001 and 2007.

The team collected fasting blood samples using EDTA tubes at the time of cardiac catheterization, immediately prior to heparin injection. Creatinine clearance was estimated using the Cockcroft‐Gault equation. Myeloperoxidase was determined by the CardioMPO assay (Cleveland Heart Labs, Cleveland, OH, USA). TMAO, choline, and betaine levels in plasma were determined using stable isotope dilution high‐performance liquid chromatography with online electrospray ionization tandem mass spectrometry on Shimadzu LCMS‐8050 CL Triple Quadrupole mass spectrometer using d9‐(trimethyl)‐labeled internal standards.

In the study cohort, the median TMAO level was 4.8 μmol/L (interquartile range 2.9–8.0 μmol/L), which was similar between patients with extracranial carotid artery stenosis (CAS) and non‐CAS. Subjects with elevated plasma TMAO levels were more likely to be older, with diabetes, with elevated high‐sensitivity C‐reactive protein (hsCRP), as well as with lower estimated glomerular filtration rate (eGFR). In contrast, prior history of CAD, smoking status, myeloperoxidase levels, apolipoprotein B levels, and medication use, were similar across TMAO levels. The incidence of both short- and long-term death progressively increased as blood levels of TMAO rose among patients with PAD. Compared to patients with the lowest levels, those with the highest levels of TMAO were 2.7 times more likely to die of any cause during the course of the five-year study.

W. H. Wilson Tang, MD, the lead author of the study said, “TMAO testing is available for clinical use, and these findings point to the potential for TMAO to help improve selection of high-risk PAD patients. Since people who are vegetarian or vegan or who follow the Mediterranean diet has been reported to have lower TMAO levels, more aggressive dietary counseling in patients with high TMAO levels is warranted.” The study was published on October 19, 2016, in the Journal of the American Heart Association.

Related Links:
Cleveland Clinic
Cleveland Heart Labs
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Uric Acid and Blood Glucose Meter
URIT-10
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.